Cybin Inc. is a biopharmaceutical company focused on developing psychedelic-based therapies to address mental health disorders. The company operates in the pharmaceutical and healthcare markets, targeting conditions such as Major Depressive Disorder, Alcohol Use Disorder, Generalized Anxiety Disorder, and Neuroinflammation. Cybin's business model revolves around advancing its drug programs through rigorous preclinical and clinical studies, with the goal of obtaining FDA approval for its innovative treatments. The company generates revenue through the development and commercialization of its proprietary drug candidates, supported by a robust intellectual property portfolio with 50 granted or pending patent applications across six patent families. Cybin serves patients, healthcare providers, and the broader mental health community by offering groundbreaking therapeutic options. The company's scientific leadership boasts extensive experience in psychiatry, addiction, and psychedelics, having overseen 60 IND programs with the FDA and contributed to the development of multiple commercially available prescription drugs. Cybin is also committed to advancing psychedelic facilitation training to promote supportive healing in clinical settings.

Keywords: psychedelic therapies, mental health, biopharmaceutical, Major Depressive Disorder, Alcohol Use Disorder, Generalized Anxiety Disorder, Neuroinflammation, FDA approval, clinical studies, intellectual property.